---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-24-020439"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T04:08:18.184377+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro reports Q2 fiscal 2025: cash $4.1M, equity $3.8M, five Phase II trials planned in 2025

## Summary
- Net cash from financing $8.3M for six months ended Oct 31, 2024; stockholder equity improved to $3.8M from a $2.6M deficit.
- Cash increased to $4.1M from $0.4M; total liabilities reduced to $1.3M from $3.2M at April 30, 2024.
- Regained Nasdaq compliance; entered $25M preferred stock/warrant agreement and $6.5M ATM facility.
- AL001 (lithium cocrystal) to initiate five Phase II trials in 2025 with Mass General for Alzheimer's, BD, MDD, PTSD.
- ALZN002 immunotherapy trial resumption planned for 2025 after re-engaging a new CRO.

## SEC filing metadata
- accession: 0001214659-24-020439
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465924020439/0001214659-24-020439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465924020439/d12122438k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-24-020439
- JSON: https://secwatch.observer/filing/0001214659-24-020439.json
- Plain text: https://secwatch.observer/filing/0001214659-24-020439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.